OT: While waiting for CRIS to regain the recent highs, wanted to find out where others have been putting some capital to work.
I had noted awhile back that I was starting to invest in LPTN, which to me looks a lot like CRIS in 2008-9 with a strong pharma partnership (Pfizer), cash through early 2014, and a potentially disruptive product pipeline which involves targeting lipids, not proteins. Today the FDA just lifted the block on a halted trial, and the price has moved up to $0.86/share. Low market cap of less than $70B on this one. [Full Disclosure: I have purchased 3 chunks here in the range of $0.90 to $0.76.]
Also seeing some encouraging recent movement in ASTX, ARNA, AMRN as well. GALE is another one I own, has been lagging recently, but has a near-term trial catalyst coming up later this year.
thanks for your list,always nice to research other bios,LPTN-being the 1 i never came across,
ime in CRIS,AMRN,ATRS, just sold my ARNA today for some profits,may get back in!...i will add AMRN in the mid 12's and ime looking to get in on ONTY for the runup of its ph3 results for lung cancer,but waiting for a pullback?might not get it!
also a devise co. that is approved in the EU and just filed AGAIN for fda is DCTH,nice technolgy for administuring chemo directly to the organs--specifily the liver,but watch for off label
many others ime watching but these are the ones ime in or are next
RNN--just received top-line data results on there ph2-pancreatic cancer compound,which is already partnered w/TEVA
this ticker ive had on radar for years---seen the 15% gain today.....
on another note-got in on LPTN today,buy order finally filled at .86-hopefully it will get some needed coverage,and onto radar... also got some SSPI---its gotta bounce from here.....and could not wait anylonger onn AMRN--Added there...
Good to hear from you. I will definitely take another look at DCTH. We've had some good shared input here on other bio names .... beginning to think that the Y! board redesign has forever scattered a knowledgeable group, and that's a shame.